NCT02633852View on ClinicalTrials.gov

Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 24, 2016

Primary Completion Date

August 28, 2018

Study Completion Date

September 6, 2018

Conditions
Diabetic Macular Edema (DME)
Interventions
DRUG

Aflibercept

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Hadassah Medical Organization

OTHER